lndiaRF to acquire API, CRAMS business of Ind-Swift Labs

IndiaRF will acquire the active pharmaceutical ingredients (API) and contract research and manufacturing services (CRAMS) business of Ind-Swift Labs for a consideration of Rs 1,650 crore. ET first reported on this transaction on July 21 this year. The acquisition will be done through Synthimed Labs, a portfolio company of India Resurgence Fund

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/p8YIcXq
via IFTTT